Contrasting of Cellular Biomedicine Group Inc. (CBMG) and KemPharm Inc. (NASDAQ:KMPH) – The EN Herald

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) and KemPharm Inc. (NASDAQ:KMPH), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of the two firms.

Valuation and Earnings

Table 1 highlights Cellular Biomedicine Group Inc. and KemPharm Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Cellular Biomedicine Group Inc. and KemPharm Inc.

Risk and Volatility

Cellular Biomedicine Group Inc.s 2.67 beta indicates that its volatility is 167.00% more volatile than that of Standard & Poors 500. KemPharm Inc.s 33.00% more volatile than Standard & Poors 500 volatility due to the companys 1.33 beta.

Liquidity

The Current Ratio and a Quick Ratio of Cellular Biomedicine Group Inc. are 4.4 and 4.4. Competitively, KemPharm Inc. has 1 and 1 for Current and Quick Ratio. Cellular Biomedicine Group Inc.s better ability to pay short and long-term obligations than KemPharm Inc.

Analyst Ratings

The Ratings and Recommendations for Cellular Biomedicine Group Inc. and KemPharm Inc. are featured in the next table.

Cellular Biomedicine Group Inc.s consensus price target is $23, while its potential upside is 60.39%. Competitively KemPharm Inc. has an average price target of $1.05, with potential upside of 28.83%. Based on the analysts belief we can conclude, Cellular Biomedicine Group Inc. is looking more favorable than KemPharm Inc.

Institutional and Insider Ownership

Cellular Biomedicine Group Inc. and KemPharm Inc. has shares held by institutional investors as follows: 23.8% and 33.5%. 37.14% are Cellular Biomedicine Group Inc.s share held by insiders. On the other hand, insiders held about 0.5% of KemPharm Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Cellular Biomedicine Group Inc.s stock price has smaller decline than KemPharm Inc.

Summary

Cellular Biomedicine Group Inc. beats KemPharm Inc. on 8 of the 9 factors.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continued here:
Contrasting of Cellular Biomedicine Group Inc. (CBMG) and KemPharm Inc. (NASDAQ:KMPH) - The EN Herald